CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Pharmaceutical Technology
Original article

Roche agrees to $1bn deal with Dualitas for bispecific antibody research

PartnershipBispecific antibodiesPositive
AI Analysis

Summary

Roche and Dualitas Therapeutics have entered a research and licence agreement valued at $1 billion to develop bispecific antibodies for inflammation and immunology diseases.

Importance:7/10
Sentiment:
0.70
partnershiplicensingbispecific antibodiesI&Ideal
Related Companies

Read the original article

Published by Pharmaceutical Technology on September 18, 2026 8:29 AM

Read Original